Rollins John Woodson 4

What Happened
John Woodson Rollins, a director of 20/20 Biolabs, had his holdings of Series A and Series A‑2 preferred stock automatically converted into common stock on February 19, 2026, upon the company’s listing on the Nasdaq Capital Market. The filing shows conversions of 13,029 shares (Series A) and 6,135 shares (Series A‑2), for a total of 19,164 common shares acquired. The conversion reported a $0.00 per‑share cash price (no cash changed hands); the preferred interests were concurrently recorded as disposed (extinguished) as derivative securities.

Key Details

• Transaction date: February 19, 2026 (conversion upon Nasdaq listing).
• Report filed: February 23, 2026 (timely relative to the Feb 19 transaction).
• Shares acquired: 13,029 (Series A) + 6,135 (Series A‑2) = 19,164 common shares.
• Price: $0.00 per share (conversion, not a cash purchase). Total cash value reported: $0.
• Transaction code: C = conversion of derivative security. The filing shows matching “acquired” common shares and “disposed” derivative entries.
• Footnotes: F1 and F2 state the Series A and Series A‑2 preferred shares automatically converted into an equivalent number of common shares upon Nasdaq listing; both series had no expiration date.
• Shares owned after the transaction: not provided in the summary data here—see the full Form 4 for total beneficial ownership.
• Filing status: appears timely (filed 2 business days after the transaction date).

Context
This was an automatic corporate conversion tied to the company’s Nasdaq listing, not an open‑market buy or sale by the director. Conversions like this are routine corporate events that convert preferred instruments into common stock and do not, by themselves, indicate insider buying or selling sentiment. For full details on post‑conversion ownership and any other insider transactions, consult the complete Form 4 (Accession No. 0001213900-26-019456).